AR120821A1 - Forma cristalina a de la sal metansulfonato de un compuesto aminopirimidina y método de preparación y aplicación de la misma - Google Patents
Forma cristalina a de la sal metansulfonato de un compuesto aminopirimidina y método de preparación y aplicación de la mismaInfo
- Publication number
- AR120821A1 AR120821A1 ARP200103555A ARP200103555A AR120821A1 AR 120821 A1 AR120821 A1 AR 120821A1 AR P200103555 A ARP200103555 A AR P200103555A AR P200103555 A ARP200103555 A AR P200103555A AR 120821 A1 AR120821 A1 AR 120821A1
- Authority
- AR
- Argentina
- Prior art keywords
- crystalline form
- aminopyrimidine compound
- compound
- salt
- aminopyrimidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente provee una forma cristalina A de la sal metansulfonato de un compuesto aminopirimidina. El patrón de XRPD de esta forma cristalina tiene picos característicos en el ángulo de difracción 2q (± 0,2º) de 11,06 ± 0,2º, 12,57 ± 0,2º, 13,74 ± 0,2º, 14,65 ± 0,2º, 15,48 ± 0,2º, 16,58 ± 0,2º, 17,83 ± 0,2º, 19,20 ± 0,2º, 19,79 ± 0,2º, 20,88 ± 0,2º, 22,05 ± 0,2º, 23,06 ± 0,2º, 24,23 ± 0,2º, 25,10 ± 0,2º, 25,71 ± 0,2º, 26,15 ± 0,2º, 27,37 ± 0,2º, 27,42 ± 0,2º (mostrado como Figura 3). También se provee el método de preparación de la forma cristalina A. La forma cristalina A de la sal metansulfonato del compuesto aminopirimidina de la presente tiene buena solubilidad y elevada biodisponibilidad en animales, la cual puede ser utilizada para tratar o prevenir enfermedades o condiciones médicas mediadas por mutaciones del factor de crecimiento epidérmico (EGFR) (activación o resistencia a drogas), especialmente cánceres en mamíferos, especialmente humanos. Reivindicación 1: Una forma cristalina A de la sal metansulfonato de un compuesto aminopirimidina, en donde el compuesto aminopirimidina es un compuesto de fórmula (1) y el espectro de XRPD de la forma cristalina A tiene picos característicos en el ángulo de difracción 2q (± 0,2º) de 12,57, 13,74, 14,65, 15,48, 16,58, 17,83, 19,20, 19,79, 22,05, 24,23, 25,10, 26,15, 27,37, 27,42.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911311034.1A CN111100117B (zh) | 2019-12-18 | 2019-12-18 | 氨基嘧啶类化合物甲磺酸盐的晶型a及其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR120821A1 true AR120821A1 (es) | 2022-03-23 |
Family
ID=70422824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200103555A AR120821A1 (es) | 2019-12-18 | 2020-12-18 | Forma cristalina a de la sal metansulfonato de un compuesto aminopirimidina y método de preparación y aplicación de la misma |
Country Status (4)
| Country | Link |
|---|---|
| CN (1) | CN111100117B (es) |
| AR (1) | AR120821A1 (es) |
| TW (1) | TW202128666A (es) |
| WO (1) | WO2021121146A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111100117B (zh) * | 2019-12-18 | 2021-02-19 | 上海倍而达药业有限公司 | 氨基嘧啶类化合物甲磺酸盐的晶型a及其制备方法和应用 |
| KR20240063865A (ko) * | 2021-07-13 | 2024-05-10 | 아세아 테라퓨틱스 인코포레이티드 | 헤테로사이클릭 화합물 및 이의 용도 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI675028B (zh) * | 2014-07-24 | 2019-10-21 | 美商貝達醫藥公司 | 做為週期素依賴型激酶（ｃｄｋ）抑制劑之2-ｈ-吲唑衍生物及其醫療用途 |
| CN105085489B (zh) * | 2014-11-05 | 2019-03-01 | 益方生物科技（上海）有限公司 | 嘧啶或吡啶类化合物、其制备方法和医药用途 |
| SG11201809931YA (en) * | 2016-05-11 | 2018-12-28 | Beta Pharma Inc | 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers |
| MX2018015508A (es) * | 2016-06-17 | 2019-04-11 | Beta Pharma Inc | Sales farmaceuticas de n-(2-(2-dimetilamino)etoxi)-4-metoxi-5-((4- (1-metil-ih-indol-3-il)pirimidin-2-il)amino)fenil)acrilamida y formas cristalinas de las mismas. |
| CN110799191B (zh) * | 2017-06-16 | 2023-05-26 | 贝塔制药有限公司 | N-(2-(2-(二甲氨基)乙氧基)-4-甲氧基-5-((4-(1-甲基-1h-吲哚-3-基)嘧啶-2-基)氨基)苯基)丙烯酰胺及其盐的药物制剂 |
| CN111100117B (zh) * | 2019-12-18 | 2021-02-19 | 上海倍而达药业有限公司 | 氨基嘧啶类化合物甲磺酸盐的晶型a及其制备方法和应用 |
-
2019
- 2019-12-18 CN CN201911311034.1A patent/CN111100117B/zh active Active
-
2020
- 2020-12-11 WO PCT/CN2020/135661 patent/WO2021121146A1/zh active Application Filing
- 2020-12-18 TW TW109145163A patent/TW202128666A/zh unknown
- 2020-12-18 AR ARP200103555A patent/AR120821A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021121146A1 (zh) | 2021-06-24 |
| CN111100117A (zh) | 2020-05-05 |
| CN111100117B (zh) | 2021-02-19 |
| TW202128666A (zh) | 2021-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123210T1 (el) | 2-(2,4,5-υποκατεστημενα-ανιλινο) παραγωγα πυριμιδινης ως ρυθμιστες egfr χρησιμα για τη θεραπευτικη αντιμετωπιση του καρκινου | |
| CY1119487T1 (el) | Αναστολεις κιναζολινης των ενεργοποιητικων μεταλλαγμενων μορφων του υποδοχεα του επιδερμικου αυξητικου παραγοντα | |
| CY1125051T1 (el) | Συντηγμενη ενωση αναστολεα jak ιμιδαζο-πιπεριδινης | |
| CY1124680T1 (el) | Παραγωγα 8-[6-[3-(αμινο)προποξυ]-3-πυριδυλο]-1-ισοπροπυλο-ιμιδαζο[4,5-c]κινολιν-2-ονης ως εκλεκτiκοι ρυθμιστες κινασης μεταλλαγμενης αταξιας τελαγγειεκτασιας (atm) για τη θεραπευτικη αγωγη του καρκινου | |
| ECSP20078230A (es) | Sales de un inhibidor de fgfr | |
| PH12016501651A1 (en) | Triazine compound and use thereof for medical purposes | |
| CN107548391A8 (zh) | 嘧啶或吡啶类化合物、其制备方法和医药用途 | |
| AR120821A1 (es) | Forma cristalina a de la sal metansulfonato de un compuesto aminopirimidina y método de preparación y aplicación de la misma | |
| WO2015042085A3 (en) | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | |
| CA2925624C (en) | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | |
| CY1120836T1 (el) | Ενωσεις 1,3,4-θειαδιαζοαης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου | |
| EA201592254A1 (ru) | Производные пиразолопирролидин-4-она и их применение при лечении заболевания | |
| JP2013521316A5 (es) | ||
| WO2016168637A3 (en) | Cyclopenta[d]pyrimidines and substituted cyclopenta[d]pyrimidines as antitubulin and microtubule targeting agents, monocyclic pyrimidines as tubulin inhibitors, and pyrrolopyrimidines as targeted antifolates and tubulin and multiple receptor tyrosine kinase inhibition and antitumor agents | |
| UA109736C2 (uk) | Поліморфна форма мезилатної солі 2-(2,4,5-заміщеного аніліно)піримідину (варіанти) | |
| TH149236B (th) | อนุพันธ์ 2-(2,4,5-แทนที่-อะนิลิโน)ไพริมิดีนที่เป็นตัวควบคุม egfr เป็นประโยชน์ในการรักษาโรคมะเร็ง | |
| EA201990482A1 (ru) | Производные 2-(2,4,5-замещенного анилино)пиримидина в качестве модуляторов egfr, полезных для лечения рака | |
| UA96488U (uk) | Спосіб лікування порушень гемоваскулярного гемостазу у хворих на ішемічну хворобу серця |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |